These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8731722)

  • 21. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.
    Fontaine C; Guiard-Schmid JB; Slama L; Essid A; Lukiana T; Rondeau E; Pialoux G
    AIDS; 2005 Nov; 19(16):1927-8. PubMed ID: 16227807
    [No Abstract]   [Full Text] [Related]  

  • 22. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP; Jagroon IA
    Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract]   [Full Text] [Related]  

  • 23. Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
    Murphy MJ; Duncan A; Vallance BD; Packard CJ; O'Reilly DS
    Postgrad Med J; 1995 Aug; 71(838):498-500. PubMed ID: 7567762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy.
    Yildiz A; Gucuk E; Cay S
    Acta Cardiol; 2008 Aug; 63(4):515-7. PubMed ID: 18795591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
    Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
    Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
    Harvengt C
    Acta Clin Belg; 1991; 46(2):117-9. PubMed ID: 1649529
    [No Abstract]   [Full Text] [Related]  

  • 27. Implication of fibrate therapy for homocysteine.
    Goffin E; Jamar F; Desager JP; Devuyst O
    Lancet; 1999 Oct; 354(9185):1209. PubMed ID: 10513738
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute muscular syndrome after bezafibrate.
    Bock KD
    Klin Wochenschr; 1981 Dec; 59(23):1321. PubMed ID: 7311399
    [No Abstract]   [Full Text] [Related]  

  • 29. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
    Francik R; Kryczyk J; Francik S
    Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability of fibric acids. Comparative data and biochemical bases.
    Sirtori CR; Calabresi L; Werba JP; Franceschini G
    Pharmacol Res; 1992; 26(3):243-60. PubMed ID: 1437989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Fibrate-induced increase in serum creatinine levels: two cases].
    Décaudin B; Beraud G; Lannoy D; Semjen E; Wierre L; Horrent S; Résibois JP; Azar R; Odou P
    Therapie; 2005; 60(6):601-2. PubMed ID: 16555504
    [No Abstract]   [Full Text] [Related]  

  • 33. [Autoimmune hepatitis induced by fibrates].
    Ganne-Carrié N; de Leusse A; Guettier C; Castera L; Levecq H; Bertrand HJ; Plumet Y; Trinchet JC; Beaugrand M
    Gastroenterol Clin Biol; 1998 May; 22(5):525-9. PubMed ID: 9762291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
    Milionis H
    Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO; Hjelm CJ; Canepo-Anson R
    Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract]   [Full Text] [Related]  

  • 36. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ; O'Bryan-Tear CG
    Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
    Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
    JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
    Lupp A; Karge E; Deufel T; Oelschlägers H; Fleck C
    Arzneimittelforschung; 2008; 58(5):225-41. PubMed ID: 18589557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of various fibrates on serum alkaline phosphatase activity.
    Ganotakis E; Tsimihodimos V; Bairaktari E; Rizos E; Athyros V; Seferiades C; Elisaf M
    Atherosclerosis; 2002 Nov; 165(1):187-8. PubMed ID: 12208487
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.